Details for Patent: 9,566,234
✉ Email this page to a colleague
Which drugs does patent 9,566,234 protect, and when does it expire?
Patent 9,566,234 protects ARIKAYCE KIT and is included in one NDA.
This patent has forty-one patent family members in twenty-two countries.
Summary for Patent: 9,566,234
| Title: | Systems for treating pulmonary infections |
| Abstract: | Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection. |
| Inventor(s): | Perkins; Walter (Pennington, NJ), Malinin; Vladimir (Plainsboro, NJ), Li; Xingong (Robbinsville, NJ), Miller; Brian (Hamilton, NJ), Seidel; Dominique (Munchen, DE), Holzmann; Philipp (Munchen, DE), Schulz; Harald (Tuttlingen, DE), Hahn; Michael (Krailing, DE) |
| Assignee: | Insmed Incorporated (Bridgewater, NJ) |
| Application Number: | 13/899,457 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; Delivery; Dosage form; |
Drugs Protected by US Patent 9,566,234
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insmed Inc | ARIKAYCE KIT | amikacin sulfate | SUSPENSION, LIPOSOMAL;INHALATION | 207356-001 | Sep 28, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,566,234
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013266400 | ⤷ Sign Up | |||
| Australia | 2017225138 | ⤷ Sign Up | |||
| Australia | 2019204100 | ⤷ Sign Up | |||
| Australia | 2020204577 | ⤷ Sign Up | |||
| Brazil | 112014029010 | ⤷ Sign Up | |||
| Canada | 2870860 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
